A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA) - RA study

Astra Zeneca0 个研究点目标入组 26 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

Trial ended prematurely

•1. Provision of informed consent prior to any study specific procedures
•2. Male and female patients aged 18 through 80 years at screening
•3. Established RA diagnosis according to the 2010 American College of Rheumatology (ACR)/EULAR classification or the 1987 criteria
•4. Active RA (DAS28-CRP score >= 3.2) with at least 3 swollen joints and 3 tender joints using the DAS28 joint count
•5. Patients must have be on stable dosing of conventional and/or s.c./i.v biological DMARDs for the last 8 weeks prior to Visit 1
•6. CRP levels >5mg/L at screening if seronegative for RF and anti-CCP Ab, or >2mg/L if seropositive for either marker
•7. BMI between 18 and 35 (inclusive)
•8. Negative pregnancy test (serum) for female subjects of childbearing potential.

•1. History or current inflammatory rheumatic disease other than RA (secondary Sjogren*s syndrome excluded)
•2. History or current clinically important disease which may either put the subject at risk because of participation in the study, or influence the results or the subject*s ability to participate in the study
•3. Any clinical contraindications to treatment with steroids
•4. Oral or parenteral steroids (beyond study medication) 8 weeks prior to study start and during the study. Stable use and dose of topical and inhaled steroids for longer than 4 w prior to randomization is acceptable
•5. Use of any prohibited medication during the study or if the required washout time of such medication was not adhered to (for details see Section 7.7.1)
•6. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar class to study drugs
•7. Any concomitant medications that are known to be associated with Torsades de Pointes, for additional information see Section 7.7.1)
•8. Any clinically significant ECG; vital signs or laboratory abnormalities identified at screening or prior to randomisation

发起方

Astra Zeneca